*我如何在我的研究論文或技術文件的引用加入內容？ (PART B)
*學術英文投稿教學影片 (162) : Data Citation Index
*強有力的動詞 (精確英文寫作) 英文編修訓練 (9 / 14)
*醫療英文論文組織寫作 (8) : (第一部分:背景)
Academic publishing news 學術出版新聞
*請使用方括號 [ ] ，說明信息來源丟失。這種做法通常發生在來源已損壞且無法讀取。
學術英文投稿教學影片 (162) : Data Citation Index
Traditionally, to guarantee the quality of LED, the packaging factory is used to relying on human inspectors. LEDs produce diversity type of defects containing surface stains, wrong coating, foreign marks and contour defects in the manufacturing process, while it will destroy the whole packaging ribbon if anyone is wrong polar orientation or over turn in the packaging process.
In practice, ensuring LED quality necessitates that the packaging factory depends on human inspectors. LEDs produce diverse defects involving surface stains, wrong coatings, foreign marks and contour defects during manufacturing, subsequently destroying the entire packaging ribbon in case of an erroneous polar orientation or a turnover during the packaging process.
As supply chain of LED manufacturers face competition from raw wafers to packaging, a greater emphasis for packaging factory is being placed on responsiveness to downstream vendors.
As the supply chain of LED manufacturers competes with producers of raw wafers to packaging, packaging factories must increasingly respond to downstream vendors.
Results of this study provide a demonstration in manufacturing cost reduction by using of early-warning model for the power failure crisis, get further with providing more accurate reliability specifications for higher products reliability, to effectively solve the problems of product quality surplus and parts inventory excess.
Results of this study demonstrate the effectiveness of the proposed early-warning model in reducing manufacturing costs during a power failure crisis, subsequently achieving accurate reliability specifications to enhance enhanced product reliability and resolve problems involving a surplus in product quality and excess of parts inventory.
Although merger is one of the strategies for the company which is goingto expand, the long term result can have far reaching influence like R&D capability enhancement or destruction. The merger can also help or harm the whole industry, and even the general public, because of the close relation between drugs and public health.
Although a merger represents an effective strategy for company expansion, the long term outcome can either enhance or inhibit R&D capabilities of the entire industry, as well as the general public since pharmaceuticals and public health are closely related.
研究建構 : 你研究的主題是什麼? 你的讀者可以明瞭研究的內容嗎?
研究問題 : 你的研究裡有你試著要解決或是想更進一步瞭解的問題嗎?
研究問題的量化 : 你要如何量化問題來讓你的讀者明白之前文獻研究所遇到的量化限制?
研究問題的中心 : 如果問題沒被解決或是充分瞭解, 這對研究的讀者會有多大的負面衝擊?
研究建構 The conventional means of treating coronary artery disease is percutaneous transluminal coronary angioplasty (PTCA) combining stents. However, according to the results of a three-year follow up study, the restenosis rate approaches 25%, necessitating a more effective treatment procedure to decrease this rate.
研究問題 Conventional stent belongs to a foreign body for humans, easily inducing smooth muscle proliferation. If the stent is an eluted drug on its surface, avoiding the drug run off in a relatively short time and determining the most optimal dose area of priority concern. The inability to resolve this problem results in recurrent PTCA treatment for 20%-30% of all CAD patients.
研究問題的量化 For instance, a concentration under 10-2 ug for the eluted drug makes it impossible to control smooth muscle proliferation. However, a concentration exceeding 1 ug would be toxic, subsequently inducing an aneurysm. Eluted with a polymer technique, the drug is classified according to the speed of release: slow, medium or fast release. Exactly which approach is the most effective one must be determined.
研究問題的中心 The inability of the stent to resist the proliferation of a smooth muscle makes it impossible to decrease the incidence rate of in-stent restenosis. To avoid this situation, much effort has been expended in developing an effective drug that prevents the further proliferation of smooth muscles.